Pulse radiation to help immunotherapy work better in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if a special type of radiation (pulse radiotherapy) can help your immune system fight cancer when it's not responding well to immunotherapy. It's for people with lung cancer that has spread to five or more areas and is growing despite treatment with PD(L)-1 inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently receiving a type of immunotherapy called a PD(L)-1 inhibitor.
- Your cancer has gotten worse (grown or spread) while on this treatment, including in at least 5 different spots in your body.
- All of your cancer spots are safe to treat with radiation, according to your doctor.
- You can have a brain tumor, but it must be treated with standard care first.
- You are not pregnant, breastfeeding, or have a history of lung inflammation (pneumonitis) or an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
This trial tests a personalized combination of radiation and immunotherapy for people with locally advanced non-small cell lung cancer that has a high level of a protein called PD-L1. It aims to improve treatment by tailoring the therapy to each patient's tumor.
This trial tests a combination of targeted radiation (SBRT) and an immunotherapy drug (puterizumab) for people whose non-small cell lung cancer has spread to the lungs after previous immunotherapy. The goal is to see if the combination can help control the cancer.
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.